We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+29.57%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.61B
AUM Growth
+$310M
Cap. Flow
+$124M
Cap. Flow %
7.72%
Top 10 Hldgs %
66.37%
Holding
50
New
7
Increased
9
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$92.8M
2
IMGO
Imago BioSciences, Inc. Common stock
IMGO
+$25.4M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$10.7M
4
VRNA
Verona Pharma
VRNA
+$9.54M
5
KALV
KalVista Pharmaceuticals
KALV
+$8.93M

Top Sells

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$26.7M
2
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
+$15.2M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$9.31M
4
PCVX icon
Vaxcyte
PCVX
+$5.89M
5
MGNX icon
MacroGenics
MGNX
+$2.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Miscellaneous 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$163M 10.15%
9,758,359
– –
IMGO
2
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$143M 8.91%
3,987,207
+1,015,933
+34% +$25.4M
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$2.99B
$129M 7.99%
8,684,232
– –
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$114M 7.08%
4,345,559
+80,000
+2% +$1.77M
NAMS icon
5
NewAmsterdam Pharma
NAMS
$3.1B
$102M 6.33%
+9,341,551
New +$92.8M
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$1.74B
$94.4M 5.87%
3,708,838
+296,000
+9% +$6.9M
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$743M
$94.3M 5.86%
8,407,152
– –
KRYS icon
8
Krystal Biotech
KRYS
$10.4B
$79.2M 4.92%
999,737
-18,651
-2% -$1.38M
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$5.94B
$75.3M 4.68%
3,860,107
+32,326
+0.8% +$639K
VRNA
10
DELISTED
Verona Pharma
VRNA
$73.6M 4.57%
2,815,720
+716,179
+34% +$9.54M
PCVX icon
11
Vaxcyte
PCVX
$8.9B
$67M 4.17%
1,397,405
-150,000
-10% -$5.89M
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7.38B
$55.2M 3.43%
1,894,000
– –
ALLK
13
DELISTED
Allakos
ALLK
$40.3M 2.51%
4,792,000
– –
ANAB icon
14
AnaptysBio
ANAB
$1.67B
$27.9M 1.73%
899,700
– –
TARS icon
15
Tarsus Pharmaceuticals
TARS
$3.15B
$26.2M 1.63%
1,787,527
– –
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$9B
$25.9M 1.61%
1,414,823
– –
REPL icon
17
Replimune Group
REPL
$1.46B
$25.3M 1.58%
931,560
+125,293
+16% +$2.6M
COGT icon
18
Cogent Biosciences
COGT
$6.02B
$24.4M 1.52%
2,109,154
+35,000
+2% +$434K
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
$21.9M 1.36%
2,985,757
– –
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
$21.9M 1.36%
3,238,859
+1,666,667
+106% +$8.93M
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$17.8M 1.11%
5,162,348
-75,000
-1% -$214K
STRO icon
22
Sutro Biopharma
STRO
$339M
$14.4M 0.89%
177,648
– –
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$5.02B
$13.6M 0.85%
857,338
– –
SLN
24
Silence Therapeutics
SLN
$834M
$13.4M 0.84%
881,173
– –
TRVI icon
25
Trevi Therapeutics
TRVI
$2.39B
$12.9M 0.8%
6,663,590
+1,260,000
+23% +$2.48M
1
2

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2022 Portfolio in Review

As of Q4 2022, Frazier Life Sciences Management held 50 positions worth $1.61B, up 24% from $1.3B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Frazier Life Sciences Management deployed $124M of net new capital in Q4 2022, opening 7 new positions and adding to 9 existing holdings. Its largest new stake was NewAmsterdam Pharma: 9,341,551 shares worth $102M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $5.89M trimmed.

  • Frazier Life Sciences Management's largest Q4 2022 buy was NewAmsterdam Pharma: 9,341,551 shares worth $102M.
  • Frazier Life Sciences Management added most to Imago BioSciences, Inc. Common stock in Q4 2022, an estimated $25.4M increase.
  • Frazier Life Sciences Management's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $5.89M.
  • Frazier Life Sciences Management fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $26.7M.
  • Frazier Life Sciences Management's ten largest holdings make up 66% of its $1.61B portfolio in Q4 2022.
  • Frazier Life Sciences Management opened 7 new positions and closed 6 in Q4 2022.
  • Frazier Life Sciences Management's portfolio value rose 24% quarter-over-quarter to $1.61B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2022, filed 3 Feb 2023.